(PTI Photo)
New Delhi: Zydus Cadila has received emergency use approval from the Drugs Controller General of India (DGCI) for the use of Virafin in treating moderate Covid-19 infection in adults.
A single-dose of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID-19, Virafin will help patients recover faster and avoid much of the complications, the company said.
In a release, Cadila Health highlighted that the drug has also shown efficacy against other viral infections. Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited, said, The fact that we are able to offer a therapy which significantly reduces the viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19.
Zydus Cadila s Virafin gets DCGI nod for emergency use to treat COVID-19 patients
dnaindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dnaindia.com Daily Mail and Mail on Sunday newspapers.
Zydus Cadila s Virafin Approved For Treating Moderate COVID-19 Cases
ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.
Market Movers: Dr Reddy’s, Cadila Health surge; 112 stocks blink buy
SECTIONS
Share
Synopsis
Despite weakness in headline indices, as many as 112 stocks listed on the NSE gave buy signals based on MACD indicators. The list included PNB, JSW Energy, Zee Entertainment Enterprises, and Kotak Mahindra Bank.
Shutterstock.com For the day, the Nifty50 index ended 0.3 per cent, or 39 points, lower at 14,834.9, while the BSE-Sensex closed at 49,591.32, down 155 points or 0.3 per cent.
Related
MUMBAI: Benchmark equity indices had a tepid day today as investors remained concerned over the impact of sharp rise in COVID-19 infections on the country’s economic recovery and corporate earnings.